3.720

-0.130 (-3.38%)
Range 3.490 - 3.730   (6.88%)
Open 3.700
Previous Close 3.850
Buy Price 3.600
Buy Volume 11
Sell Price 3.690
Sell Volume 18
Volume 3,507,756
Value -
Remark
Measurement Type Value
EPS (USD) -0.779
Trailing EPS (USD) -0.779
NAV (USD) 0.568
Cash In Hand (USD) 0.434
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5.089
Price / Cash In Hand 6.661
Issued & Paid-up Shares 38,792,400
Treasury Shares -
Market Cap (M) 112.11
Par Value (USD) n.a.
Beta - 75 Days 1.093
R-Squared - 75 Days(%) 5.86
Beta - 500 Days 1.072
R-Squared - 500 Days(%) 0.05
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 08 May 2021 04:00.
Data powered by
View All Events

About BIOLINE RX LTD SPON ADS EACH REPR 15 ORD SHS

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Loading Chart...